Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Myovant Sciences Ltd
(NY:
MYOV
)
N/A
UNCHANGED
Last Price
Updated: 7:00 PM EST, Mar 9, 2023
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Myovant Sciences Ltd
< Previous
1
2
3
4
Next >
Why Myovant Sciences Shares Are Skyrocketing Monday
October 03, 2022
Myovant Sciences Ltd (NYSE: MYOV) shares are trading higher by 30.85% to $23.50 during Monday's pre-market session after the company received an acquisition offer from Sumitovant Biopharma and...
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
October 03, 2022
We're starting off the week with a breakdown of the biggest pre-market stock movers traders need to know about for Monday morning!
Via
InvestorPlace
Myovant Sciences Rejects Sumitovant/Sumitomo Pharma Buyout Offer Of $2.5B
October 03, 2022
Via
Benzinga
Why Myovant Sciences Is Trading Higher By Over 26%; Here Are 31 Stocks Moving Premarket
October 03, 2022
Gainers Wearable Devices Ltd. (NASDAQ: WLDS) rose 58% to $1.39 in pre-market trading after declining around 8% on Friday. Wearable Devices, last week, posted a 1H loss of $0.18 per share.
Via
Benzinga
Myovant Sciences: Q4 Earnings Insights
May 10, 2022
Myovant Sciences (NYSE:MYOV) reported its Q4 earnings results on Tuesday, May 10, 2022 at 07:00 AM. Here's what investors need to know about the announcement.
Via
Benzinga
Myovant, Accord Healthcare Ink Relugolix Distribution Pact For Europe In Prostate Cancer
May 09, 2022
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For August 9, 2022
August 09, 2022
Via
Benzinga
Karuna Therapeutics To $276? Plus SVB Leerink Almost Doubles Price Target On This Stock
August 09, 2022
Mizuho boosted the price target for Karuna Therapeutics, Inc. (NASDAQ: KRTX) from $190 to $276. Karuna Therapeutics shares fell 1.3% to $238.00 in pre-market trading.
Via
Benzinga
FDA Approves Myovant Sciences/Pfizer's Treatment For Endometriosis-Associated Pain
August 08, 2022
Via
Benzinga
Myovant Sciences' Relugolix For Hormone-Sensitive Prostate Cancer Approved In Europe
May 02, 2022
Via
Benzinga
Biotech Daily: Thumbs Down For Acadia's Antipsychotic Drug, Akebia Fails COVID-19 Study, Kazia's Encouraging Data In Brain Metastases
August 05, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
Myovant Sciences's Return On Invested Capital Insights
August 01, 2022
According to data from Benzinga Pro, during Q1, Myovant Sciences's (NYSE:MYOV) reported sales totaled $116.49 million. Despite a 64.17% increase in earnings, the company posted a loss of $21.24...
Via
Benzinga
Biotech Investors: August's Key PDUFA Catalysts You Must Know
July 31, 2022
Regulatory decisions have yet to pick up pace this year. July’s calendar was light, but the good news was that most decisions turned out to be positive. That said, none of the drugs approved during the...
Via
Benzinga
Recap: Myovant Sciences Q1 Earnings
July 27, 2022
Myovant Sciences (NYSE:MYOV) reported its Q1 earnings results on Wednesday, July 27, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings Myovant Sciences beat...
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
July 27, 2022
Gainers
Via
Benzinga
Daily Biotech Pulse: Teva's Opioids Settlement, Criminal Investigation Against Cassava, Durable Responses For IN8bio's Leukemia Therapy
July 27, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
Earnings Outlook For Myovant Sciences
July 26, 2022
Myovant Sciences (NYSE:MYOV) is set to give its latest quarterly earnings report on Wednesday, 2022-07-27. Here's what investors need to know before the announcement. Analysts estimate that Myovant...
Via
Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
July 07, 2022
Gainers
Via
Benzinga
Earnings Scheduled For July 27, 2022
July 27, 2022
Companies Reporting Before The Bell • Equinor (NYSE:EQNR) is projected to report earnings for its second quarter.
Via
Benzinga
FDA Accepts Myovant Sciences and Pfizer's Filing For Review In Uterine Fibroids
June 02, 2022
Myovant Sciences (NASDAQ: MYOV) and Pfizer (NASDAQ: PFE) received U.S.
Via
Benzinga
Attention Biotech Investors: Mark Your Calendar For These June PDUFA Dates
May 31, 2022
May turned out to be a month of mixed fortunes as far as regulatory reviews are concerned. New molecular entity approvals, an indicator of innovation in drug research, totaled three during the month,...
Via
Benzinga
Urovant's OAB Gene Therapy Shows Improvement In Symptoms Compared To Placebo
May 13, 2022
Urovant Sciences' interim results from a Phase 2a trial of URO-902 gene therapy were presented at the annual meeting of the American Urological Association (AUA2022). Urovant is a wholly-owned...
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
May 10, 2022
Via
Benzinga
103 Biggest Movers From Yesterday
May 11, 2022
Gainers
Via
Benzinga
77 Stocks Moving In Tuesday's Mid-Day Session
May 10, 2022
Gainers
Via
Benzinga
The Daily Biotech Pulse: Pfizer Acquires Migraine Drugmaker For $11B, Biogen Files For Second Alzheimer's Drug Approval, Longeveron CEO Leaves
May 10, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
Earnings Preview: Myovant Sciences
May 09, 2022
Myovant Sciences (NYSE:MYOV) is set to give its latest quarterly earnings report on Tuesday, 2022-05-10. Here's what investors need to know before the announcement. Analysts estimate that Myovant...
Via
Benzinga
U.S. FDA extends review of Pfizer and Myovant Sciences supplemental New Drug Application (sNDA) For MYFEMBREE by three months
May 06, 2022
The U.S. Food and Drug Administration (FDA) has extended the review period for the supplemental New Drug Application (sNDA) from Pfizer Inc.
Via
Benzinga
Here's Why This Analyst Is On Sidelines Despite European Approval Of Myovant's Relugolix For Prostate Cancer
May 02, 2022
Via
Benzinga
The Week Ahead In Biotech (May 1-7): Phathom FDA Decision, Pfizer, Vertex Pharma Lead Earnings News, Ophthalmology Conference Presentations, And More
May 02, 2022
Biotech stocks posted weekly declines yet again in the week ending April 29, taking cues from the weak broader market sentiment. Big pharma earnings, clinical readouts and pipeline updates moved stocks...
Via
Benzinga
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.